title: [Treatment of 14 cases of Castlemans disease: the experience of one centre and an overview of literature].
abstract: Castlemans disease is the term for reactive lymphocytary and plasmocytary proliferation which occurs in the unicentric (localized) form, usually without systemic symptoms, or in the generalized/multicentric form, typically with systemic symptoms (www.vzacne-diagnozy.cz). Over the past 25 years we diagnosed, treated and followed 14 histologically proven cases of Castlemans diseases. Seven patients had the localised form of the disease. In 5 of 7 cases the pathological lesion was located intrathoracically or intraabdominally and in only 2 cases it was on the surface of the body. No clinical symptoms were present in any of the patients with the unicentric form of the disease and surgical treatment led to the total removing of the disease in all of them. As opposed to that, all 7 patients with the multicentric form of Castlemans disease experienced febrile or subfebrile temperatures. Three of the 7 patients complained of severe troubling night sweats. Clinical expressions of vasculitis which was the cause of stroke, were present in 1 of 7 patients. Osteosclerotic changes on the skeleton were detected in 1 patient, who also suffered from fluid retention likely associated with this disease. Polyclonal propagation of immunoglobulins, predominantly immunoglobulin IgG type, was present in 5 of 7 patients with the multicentric form. In one case there was one complete molecule of monoclonal imunoglobuline present and in one case loose light chains κ were increased More than 1 sampling of material for histological examination of enlarged lymph nodes were needed in 6 of 7 patients for diagnosing the multicentric form of the disease. It has turned out beneficial with respect to diagnosing the disease to carry out surgical removal and histological examination of the nodes which accumulated the most fluorodeoxyglucose within PET-CT examination. The text describes experience of the treatment. In recent years the basis for the treatment has been the monoclonal antibody antiCD20 rituximab, or thalidomide and lenalidomide, or possibly their combination. The new medicine for these patients is interleukin-6 antibody called siltuximab (Sylvant), of which we have no own experience so far. Five of our seven patients with the multicentric form received treatment, 1 patient refused treatment and in one patient the signs of the disease activity are not expressed to such extent that would require treatment. The therapy containing rituximab reached complete remission in 2 patients and the therapy containing thalidomide and lenalidomide achieved the complete remission of the disease in 3 patients. In one of the above described cases the disease did not respond to the initial treatment with rituximab and remission was reached by thalidomide and lenalidomide and in one case the disease did not respond to the initial treatment with thalidomide and complete remission was reached with rituximab. Following the treatment, no patient with the multicentric form of Castlemans disease has had a relapse until now.
authors.forename: Zdeněk
authors.initials: Z
authors.lastname: Adam
authors.forename: Petr
authors.initials: P
authors.lastname: Szturz
authors.forename: Marta
authors.initials: M
authors.lastname: Krejčí
authors.forename: Renata
authors.initials: R
authors.lastname: Koukalová
authors.forename: Eva
authors.initials: E
authors.lastname: Michalková
authors.forename: Zdeněk
authors.initials: Z
authors.lastname: Řehák
authors.forename: Eva
authors.initials: E
authors.lastname: Pourová
authors.forename: Luděk
authors.initials: L
authors.lastname: Pour
authors.forename: Pavlína
authors.initials: P
authors.lastname: Volfová
authors.forename: Viera
authors.initials: V
authors.lastname: Sandecká
authors.forename: Zdeňka
authors.initials: Z
authors.lastname: Čermáková
authors.forename: Leoš
authors.initials: L
authors.lastname: Křen
authors.forename: Filip
authors.initials: F
authors.lastname: Sokol
authors.forename: Ivo
authors.initials: I
authors.lastname: Hanke
authors.forename: Igor
authors.initials: I
authors.lastname: Penka
authors.forename: Hana
authors.initials: H
authors.lastname: Petrášová
authors.forename: Sabina
authors.initials: S
authors.lastname: Ševčíková
authors.forename: Zdeněk
authors.initials: Z
authors.lastname: Král
authors.forename: Jiří
authors.initials: J
authors.lastname: Mayer
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D005871:Castleman Disease / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D000069283:Rituximab / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000069283:Rituximab; D013792:Thalidomide; D000077269:Lenalidomide; C504234:siltuximab